GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Action(s) initiated or orders passed
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Directorate of Revenue Intelligence (DRI), under India's Department of Revenue, conducted a search at GlaxoSmithKline Pharmaceuticals' registered office in Worli, Mumbai. The search was carried out under Section 105 of the Customs Act, 1962, and lasted from 27th February 2026 to 28th February 2026. The company fully cooperated with officials and responded to their queries. GSK Pharma stated that business operations continue as usual with no impact on financial, operational, or other activities. No specific allegations or violations have been disclosed beyond the customs-related search.
In the short term, this may create some negative sentiment and volatility around the stock due to the regulatory action, even though the company claims no operational impact. Investors should monitor for any further developments, as DRI searches can sometimes lead to tax/customs demands. The fact that the search completed within a day and operations are unaffected is a positive sign.